765 results about "Calcium Compounds" patented technology

The present invention is directed to the upgrading of heavy petroleum oils of high viscosity and low API gravity that are typically not suitable for pipelining without the use of diluents. It utilizes a short residence-time pyrolytic reactor operating under conditions that result in a rapid pyrolytic distillation with coke formation. Both physical and chemical changes taking place lead to an overall molecular weight reduction in the liquid product and rejection of certain components with the byproduct coke. The liquid product is upgraded primarily because of its substantially reduced viscosity, increased API gravity, and the content of middle and light distillate fractions. While maximizing the overall liquid yield, the improvements in viscosity and API gravity can render the liquid product suitable for pipelining without the use of diluents. This invention particularly relates to reducing sulfur emissions during the combustion of byproduct coke (or coke and gas), to reducing the total acid number (TAN) of the liquid product, and to reducing the hydrogen sulfide content of one, or more than one component of the product stream. The method comprises introducing a particulate heat carrier into an up-flow reactor, introducing the feedstock at a location above the entry of the particulate heat carrier, allowing the heavy hydrocarbon feedstock to interact with the heat carrier for a short time, separating the vapors of the product stream from the particulate heat carrier and liquid and byproduct solid matter, regenerating the particulate heat carrier in the presence of the calcium compound, and collecting a gaseous and liquid product from the product stream.

A pharmaceutical composition for oral administration comprising PTH, wherein the in vitro release of PTH-when tested in a dissolution test of pharmacopoeia standard-is delayed with at least 2 hours and once the release starts, at least 90% w/w such as, e.g., at least 95% or at least 99% of all PTH contained in the composition is released within at the most 2 hours. The composition may also comprises a calcium containing compound and/or a vitamin, D. In particular, PTH is administered in combination with a calcium-containing compound for the treatment or prevention of bone-related diseases, so that I) an effective amount of a calcium-containing compound is administered to lower the plasma level of endogenous PTH, and II) an effective amount of PTH is administered to obtain a peak concentration of Pm once the endogeneous PTH level is lowered. This present a potential therapeutic or prophylactic regimen for bone-related disorders including osteoporosis.

In a method of producing a fatty acid lower alkylester according to the invention, a fat & oil and a lower alcohol are caused to react with each other in the presence of a catalyst, in which triglyceride contained in the fat & oil undergoes a transesterification. The catalyst to be used in the reaction is a solid basic catalyst consisting essentially of a potassium compound and iron oxide, of a calcium compound and iron oxide, or of a potassium compound and zirconium oxide. It is possible to produce the fatty acid lower alkylester at a high reaction efficiency by this method as well as to simplify or eliminate the need of catalyst separation and recovery processes.

Compositions containing strontium fortified calcium nanoparticles and/or microparticles, and methods of making and using thereof are described herein. The strontium fortified calcium compounds contain calcium ions, calcium atoms, strontium ions, strontium atoms, and combinations thereof and one or more anions. Exemplary anions include, but are not limited to, citrate, phosphate, carbonate, and combinations thereof. The particles can be formulated for enteral or parenteral administration by incorporating the particles into a pharmaceutically carrier. The compositions can further contain one or more active agents useful for bone diseases or disorders, such as vitamin D, growth factors, and combinations thereof. The compositions can be used to treat or prevent one or more bone diseases or disorders of the bone, such as osteoporosis. Alternatively, the particles can be coated onto a substrate, such as the surface of an implant. The coatings can be used to improved biocompatibility of the implant, prevent loosening of the implant, reducing leaching of metal ions from metallic implants, and reduce corrosion. The coatings can be applied to the substrate using a variety of techniques well known in the art. In one embodiment, the coating is applied using electrophoretic deposition. The use of nano- and/or microparticles that provide high surface area helps to improve interfacial strength between the coating and the implant, which allows for the use of lower sintering temperatures. Lowering sintering temperatures minimizes or prevents thermal decomposition of the coating material and/or degradation of the implant material.

The present invention provides an alkaline battery having good heavy-loading discharge characteristics even after long-term storage at high temperatures. The alkaline battery of the present invention comprises a positive electrode containing manganese dioxide and nickel oxyhydroxide as an active material, a negative electrode containing zinc as an active material, and an alkaline electrolyte. The positive electrode further contains at least one compound selected from the group consisting of an oxygen-containing zinc compound, an oxygen-containing calcium compound, an oxygen-containing yttrium compound, and an oxygen-containing titanium compound.

The present invention relates in general to implantable flexible bone composites, and method for preparing the same. The flexible bone composite includes at least one polymeric layer and at least one calcium-containing layer. The polymeric layer can be a polymeric layer including a synthetic polymer. The calcium-containing layer can include a calcium compound such as β-Ca₃(PO₄)₂. The flexible bone composites of the invention are useful as bone void fillers and have improved handling characteristics.

Calcium amino acid chelate complexes for fortification of dairy products and oleaginous foods, dairy products and oleaginous foods fortified with calcium amino acid chelate complexes, and methods of preparing calcium amino acid chelate complexes are disclosed and described. The calcium amino acid chelate complexes of the present invention are stable, palatable, and bioavailable. Preparation steps include reacting a calcium compound, an amino acid ligand, a pH adjuster, and, optionally, a stabilizing/suspending agent in an aqueous environment.

A bone or dental implant material in the form of a paste includes a mixture of calcium phosphate and/or calcium-containing powders and a solution that is (1) an acidic calcium phosphate solution saturated with respect to one or more calcium phosphate compounds, (2) a concentrated acid solution, or (3) salt solutions with a cationic component other than calcium. The paste is stable, resistant to washout and will form hydroxyapatite and harden relatively rapidly to a cement.

A cage for facilitating fusion of bones, such as vertebrae, or fusion of adjacent bone surfaces is disclosed. In one form, the cage includes a plurality of spaced apart walls comprising a biodegradable polymeric material (e.g., polycaprolactone); an osteoconductive mineral coating (e.g., a calcium compound) on at least a portion of the walls; and a bioactive agent (e.g., a bone morphogenetic protein) associated with the polymeric material and/or the coating. The bioactive agent is present in amount that induces ossification between the bones or adjacent bone surfaces. The cage may also include a fixation plate connected to at least one of the walls.

The present invention is directed to the upgrading of heavy petroleum oils of high viscosity and low API gravity that are typically not suitable for pipelining without the use of diluents. It utilizes a short residence-time pyrolytic reactor operating under conditions that result in a rapid pyrolytic distillation with coke formation. Both physical and chemical changes taking place lead to an overall molecular weight reduction in the liquid product and rejection of certain components with the byproduct coke. The liquid product is upgraded primarily because of its substantially reduced viscosity, increased API gravity, and the content of middle and light distillate fractions. While maximizing the overall liquid yield, the improvements in viscosity and API gravity can render the liquid product suitable for pipelining without the use of diluents. This invention particularly relates to reducing sulfur emissions during the combustion of byproduct coke (or coke and gas) and to reducing the total acid number (TAN) of the liquid product. The method comprises introducing a particulate heat carrier into an up-flow reactor, introducing the feedstock at a location above the entry of the particulate heat carrier, allowing the heavy hydrocarbon feedstock to interact with the heat carrier for a short time, separating the vapors of the product stream from the particulate heat carrier and liquid and byproduct solid matter, regenerating the particulate heat carrier in the presence of the calcium compound, and collecting a gaseous and liquid product from the product stream.

A pharmaceutical composition for nasal administration exhibits an improved bioavailability of a biologically active polypeptide, the active ingredient of the pharmaceutical composition. Specifically, the composition is prepared by uniformly dispersing and embedding a biologically active acidic polypeptide having an isoelectric point of 7 or lower on the surfaces of a polyvalent metal compound carrier with the help of an additive capable of dispersing and embedding the polypeptide on the surfaces of the carrier. The polyvalent metal compound carrier is a metal compound with a valent of 2 or higher that is either insoluble or little soluble in water, examples being aluminum compounds, calcium compounds, magnesium compounds, silicone compounds, iron compounds, and zinc compounds.

Calibration and reference samples with reduced cross-sectional areas encased within imaging tables or couch pads have low attenuation properties and provide patient comfort. The samples are stable and provide reproducible images without artifacts. The torso-length samples avoid positioning errors and misalignment. Sample density or mass calibration materials include calcium compounds representative of bone and calcifications, iodine compounds for contrast angiography, gadolinium compounds for MRI, and fat and tissue equivalent materials. Density corrections for variable patient scatter and imperfect image reconstructions improve quantitative measurement. Automated computer methods detect the samples and record readings on all images over the extent of the scans without operator interaction. Spatial references function as location references and enable spatial correction of device imperfections such as point spread function (PSF) or motion for improved images. Comparative analysis of backward and forward projections corrects images based on simultaneous imaging of the references of known properties.

A granular adsorbent composition suitable for desulfurization of cracked gasoline or diesel fuel streams is provided by adding a catalyst selected from the group consisting of calcium sulfate, calcium aluminate, Calcium compounds of calcium phosphate and calcium silicate to increase porosity and improve passivation resistance, wherein said accelerator is a metal, metal oxide or metal oxide precursor, wherein said metal is selected from the group consisting of cobalt, nickel, iron, manganese , copper, molybdenum, tungsten, silver, tin and vanadium or mixtures thereof, the valence of said promoter has been substantially reduced to 2 or lower. Also provided is a process for the preparation of such an adsorbent system and its use for desulfurization of cracked gasoline and diesel fuel.

Calcium peroxyphosphate compounds and dental compositions comprising these compounds that combine both whitening/stain removal of teeth with remineralization are disclosed. The calcium peroxyphosphate compounds are capable of releasing, in an aqueous environment, whitening and remineralization effective amounts of calcium ion, phosphate ion, and active oxygen. Preferred compounds are calcium peroxymonophosphate or calcium diperoxymonophosphate compounds. These compounds may be used in humans and other animals, including other mammals.

The invention relates to calcium modified biochar and a preparation method and application thereof. Biochar serves as a matrix of the adsorbent, and the surface of the matrix is loaded with a calcium compound. The preparation method comprises the particular steps that biomass powder is immersed into an aqueous calcium ion solution to be loaded with calcium ions; dried biomass powder loaded with the calcium ions is prepared through the steps of vacuum filtering, washing and drying; the dried biomass powder loaded with the calcium ions is pyrolyzed for two hours at 500 DEG C through a tubular atmosphere furnace in a N2 atmosphere, and the calcium modified biochar is obtained. The calcium modified biochar has a good adsorption effect on phosphate. The calcium modified biochar has the advantages that the raw materials are rich, the preparation cost is low, there are more adsorption sites, the adsorbing capacity is large, and secondary pollution does not exist. The calcium modified biochar can further serve as a fertilizer capable of slowly releasing nutrient elements and a soil improvement agent after absorbing the phosphorus element in water and can be used for phosphorus-containing wastewater treatment and soil improvement.

Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof.

The invention provides a method of preparing an implantable article with a bioactive strontium-substituted ceramic apatite coating. The method involves incubating a biocompatible substrate surface that is not coated with a calcium-containing compound with a composition comprising (i) strontium ions, (ii) calcium ions, (iii) phosphate ions, and (iv) a liquid carrier.

The invention belongs to a building material and particularly relates to an algae calcium compound material, a decorative panel and a production method. Kieselguhr and a calcium-containing inorganic building material substrate are hydrated, gelled and compounded, thereby forming the algae calcium compound material, wherein the calcium-containing inorganic building material substrate is selected from one or more of hemihydrate calcium sulfate, calcium phosphate and calcium aluminate; preferably, the components are mixed at a weight ratio of the calcium-containing inorganic building material substrate to kieselguhr to enhanced fiber chopped strand to water-based gel solution to chemical auxiliaries being 100:(10-50): (1.2-2.0): (50-65): (5-10); and the raw materials are subjected to raw material pretreatment, mixing and stirring, filling and molding, maintaining and drying, and surface treatment, thereby forming a decorative material product. The excellent plasticity and environmental friendliness of the novel compound material are fully excited while the microporosity of the kieselguhr is utilized to endow the material with excellent functions of humidifying and absorbing harmful gas, such as, formaldehyde, and the like, and the environmental protecting functions, such as sterilization, and the like.

A cage for facilitating fusion of bones, such as vertebrae, or fusion of adjacent bone surfaces is disclosed. In one form, the cage includes a plurality of spaced apart walls comprising a biodegradable polymeric material (e.g., polycaprolactone); an osteoconductive mineral coating (e.g., a calcium compound) on at least a portion of the walls; and a bioactive agent (e.g., a bone morphogenetic protein) associated with the polymeric material and/or the coating. The bioactive agent is present in amount that induces ossification between the bones or adjacent bone surfaces. The cage may also include a fixation plate connected to at least one of the walls.